{"title":"PPAR Ω 口袋:药物开发的新机遇。","authors":"Åsmund Kaupang, Trond Vidar Hansen","doi":"10.1155/2020/9657380","DOIUrl":null,"url":null,"abstract":"<p><p>The past decade of PPAR<i>γ</i> research has dramatically improved our understanding of the structural and mechanistic bases for the diverging physiological effects of different classes of PPAR<i>γ</i> ligands. The discoveries that lie at the heart of these developments have enabled the design of a new class of PPAR<i>γ</i> ligands, capable of isolating central therapeutic effects of PPAR<i>γ</i> modulation, while displaying markedly lower toxicities than previous generations of PPAR<i>γ</i> ligands. This review examines the emerging framework around the design of these ligands and seeks to unite its principles with the development of new classes of ligands for PPAR<i>α</i> and PPAR<i>β/δ</i>. The focus is on the relationships between the binding modes of ligands, their influence on PPAR posttranslational modifications, and gene expression patterns. Specifically, we encourage the design and study of ligands that primarily bind to the <i>Ω</i> pockets of PPAR<i>α</i> and PPAR<i>β/δ</i>. In support of this development, we highlight already reported ligands that if studied in the context of this new framework may further our understanding of the gene programs regulated by PPAR<i>α</i> and PPAR<i>β/δ</i>. Moreover, recently developed pharmacological tools that can be utilized in the search for ligands with new binding modes are also presented.</p>","PeriodicalId":20439,"journal":{"name":"PPAR Research","volume":null,"pages":null},"PeriodicalIF":3.5000,"publicationDate":"2020-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7351019/pdf/","citationCount":"0","resultStr":"{\"title\":\"The PPAR <i>Ω</i> Pocket: Renewed Opportunities for Drug Development.\",\"authors\":\"Åsmund Kaupang, Trond Vidar Hansen\",\"doi\":\"10.1155/2020/9657380\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The past decade of PPAR<i>γ</i> research has dramatically improved our understanding of the structural and mechanistic bases for the diverging physiological effects of different classes of PPAR<i>γ</i> ligands. The discoveries that lie at the heart of these developments have enabled the design of a new class of PPAR<i>γ</i> ligands, capable of isolating central therapeutic effects of PPAR<i>γ</i> modulation, while displaying markedly lower toxicities than previous generations of PPAR<i>γ</i> ligands. This review examines the emerging framework around the design of these ligands and seeks to unite its principles with the development of new classes of ligands for PPAR<i>α</i> and PPAR<i>β/δ</i>. The focus is on the relationships between the binding modes of ligands, their influence on PPAR posttranslational modifications, and gene expression patterns. Specifically, we encourage the design and study of ligands that primarily bind to the <i>Ω</i> pockets of PPAR<i>α</i> and PPAR<i>β/δ</i>. In support of this development, we highlight already reported ligands that if studied in the context of this new framework may further our understanding of the gene programs regulated by PPAR<i>α</i> and PPAR<i>β/δ</i>. Moreover, recently developed pharmacological tools that can be utilized in the search for ligands with new binding modes are also presented.</p>\",\"PeriodicalId\":20439,\"journal\":{\"name\":\"PPAR Research\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.5000,\"publicationDate\":\"2020-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7351019/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"PPAR Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1155/2020/9657380\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2020/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"PPAR Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1155/2020/9657380","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2020/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
The PPAR Ω Pocket: Renewed Opportunities for Drug Development.
The past decade of PPARγ research has dramatically improved our understanding of the structural and mechanistic bases for the diverging physiological effects of different classes of PPARγ ligands. The discoveries that lie at the heart of these developments have enabled the design of a new class of PPARγ ligands, capable of isolating central therapeutic effects of PPARγ modulation, while displaying markedly lower toxicities than previous generations of PPARγ ligands. This review examines the emerging framework around the design of these ligands and seeks to unite its principles with the development of new classes of ligands for PPARα and PPARβ/δ. The focus is on the relationships between the binding modes of ligands, their influence on PPAR posttranslational modifications, and gene expression patterns. Specifically, we encourage the design and study of ligands that primarily bind to the Ω pockets of PPARα and PPARβ/δ. In support of this development, we highlight already reported ligands that if studied in the context of this new framework may further our understanding of the gene programs regulated by PPARα and PPARβ/δ. Moreover, recently developed pharmacological tools that can be utilized in the search for ligands with new binding modes are also presented.
期刊介绍:
PPAR Research is a peer-reviewed, Open Access journal that publishes original research and review articles on advances in basic research focusing on mechanisms involved in the activation of peroxisome proliferator-activated receptors (PPARs), as well as their role in the regulation of cellular differentiation, development, energy homeostasis and metabolic function. The journal also welcomes preclinical and clinical trials of drugs that can modulate PPAR activity, with a view to treating chronic diseases and disorders such as dyslipidemia, diabetes, adipocyte differentiation, inflammation, cancer, lung diseases, neurodegenerative disorders, and obesity.